Implications of small reference vessel diameter in patients undergoing percutaneous coronary revascularization  by Schunkert, Heribert et al.
Implications of Small Reference Vessel
Diameter in Patients Undergoing
Percutaneous Coronary Revascularization
Heribert Schunkert, MD,*† Lari Harrell, BS,* Igor F. Palacios, MD, FACC*
Boston, Massachusetts and Regensburg, Germany
OBJECTIVES The purpose of this study was to determine whether small reference diameter of the culprit
coronary artery influences the outcome of an attempted percutaneous revascularization
procedure in the current era of interventional cardiology.
BACKGROUND Although the interventional strategy is largely determined by the size of the culprit coronary
artery, earlier quantitative studies have not shown a worse acute outcome for small reference
vessel diameter (#2.5 mm).
METHODS A total of 2,306 patients undergoing percutaneous coronary revascularization was divided in
groups with reference diameters #2.5 mm (n 5 813) or .2.5 mm (n 5 1,493). Success and
in-hospital major adverse cardiac event (death, Q-wave myocardial infarction and emergency
coronary artery bypass graft) rates between both groups were compared.
RESULTS Patients with lesions in small vessels were older and presented more frequently with female
gender, diabetes mellitus, heart failure, peripheral vascular, multivessel coronary disease and
American Heart Association/American College of Cardiology (AHA/ACC) lesion type C
(p # 0.01, each). Further, utilization of interventional devices differed markedly. In contrast
to stents (18.5% vs. 41.9%) and directional atherectomy (3.7% vs. 13.5%), conventional
balloon angioplasty (73% vs. 50%) and rotational atherectomy (16.1% vs. 8.3%) were used
more often in smaller vessels (p # 0.0001, each). Success rate was lower in the small vessel
group (92% vs. 95%; p 5 0.006). Major adverse cardiac events occurred more frequently in
small than large vessels (univariate 3.4% vs. 2.0%, p 5 0.03; multivariate odds ratio 2.1, p 5
0.02), particularly when proximal coronary segments were compared.
CONCLUSIONS Lesions in vessels with small reference diameter represent a distinct group with respect to
clinical and morphologic characteristics as well as device utilization. These lesions have lower
chances of successful percutaneous intervention and carry relatively higher risks, specifically
when located in proximal coronary segments. (J Am Coll Cardiol 1999;34:40–8) © 1999 by
the American College of Cardiology
A patient scheduled for percutaneous coronary intervention
requires careful clinical evaluation to adequately assess the
success and potential complication rate of the attempted
procedure. This consideration is largely based on patient-
related factors such as comorbidities, as well as coronary
artery–related factors such as location or morphology of the
stenosis (1). Before 1988, conventional balloon angioplasty,
the predominant method used for coronary revasculariza-
tion, was considered equally effective in small and large
vessels (2,3). Moreover, earlier studies have not shown small
vessel size to be an independent predictor associated with a
worse in-hospital outcome (1,4).
Since 1988, device technology employed for transluminal
coronary revascularization experienced considerable im-
provements. In parallel, success rates increased and compli-
cation rates declined substantially (5–8). However, most of
these new devices were preferentially used in larger vessels
(9,10). In particular, stent deployment, currently the most
frequently used strategy in many institutions (7), has been
shown to be most effective in vessels with reference diam-
eters .2.5 mm (11,12). Thus, small coronary vessels were
partially exempted from recent shifts in device technology.
We therefore reconsidered reference diameter of the coro-
nary artery as a potential factor influencing the outcome of
an attempted revascularization procedure. In particular, we
tested the predictive value of an angiographically small
culprit vessel size in 2,306 consecutive patients scheduled
for coronary intervention at a single institution who were
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prospectively analyzed by quantitative digitized coronary
angiography.
METHODS
Patient population. A total of 3,054 patients underwent
percutaneous coronary revascularization of only native cor-
onary arteries at the Massachusetts General Hospital be-
tween January 1994 and January 1997. Patients were strat-
ified into one of two distinct groups based upon reference
vessel size. A total of 748 patients received treatment in
vessels with reference diameters in both groups. By defini-
tion, these patients were excluded from the analysis. The
study population comprised the remaining 2,306 patients, of
whom 813 patients had culprit lesion(s) treated in vessels
with reference diameters #2.5 mm and 1,493 patients had
culprit lesion(s) treated in vessels with reference diameters
.2.5 mm. A total of 2,840 lesions were treated in this
patient cohort.
Clinical and periprocedural variables. Demographic,
clinical and preprocedural data were determined as part of
the routine evaluation before attempted coronary interven-
tion and entered prospectively in the interventional database
of the Massachusetts General Hospital (13). Patient demo-
graphics, coronary risk factors, preprocedural associated major
comorbidities and clinical admission syndrome including
chronic stable angina, unstable angina (includes new onset,
worsening and rest), post–myocardial infarction angina, car-
diogenic shock, evolving myocardial infarction and conges-
tive heart failure were prospectively collected as part of the
routine evaluation before attempted coronary intervention.
Coronary intervention was considered to be complicated
by a major adverse cardiac event (MACE) when death
(cardiac and noncardiac) or Q-wave myocardial infarction
occurred during the hospital stay irrespective of the time
that elapsed between the procedure and the event. Coronary
bypass surgery was considered to be a major adverse event
when performed within the first 24 h after the procedure
(emergency coronary artery bypass graft). This definition of
combined events (death, Q-wave myocardial infarction and
emergency coronary artery bypass graft) is the most fre-
quently used for analysis of adverse outcome after interven-
tional procedures (6,8,10,14). Cardiac enzymes, creatine
kinase (CK) and CK MB fraction (CK-MB) were obtained
before and at 8 and 16 h after the procedure and reviewed
daily as a part of the critical pathway of our institution. A
$2-fold increase in CK-MB above the upper limit of
normal (10 ng/ml) irrespective of total CK in the absence of
new Q waves in the electrocardiogram was considered to
indicate a non–Q-wave infarction. The combination of
major adverse events and non–Q-wave infarction consti-
tuted a secondary end point in this study. Patient charts
were reviewed daily for adverse events until hospital dis-
charge or death.
Procedural variables and quantitative coronary angiogra-
phy. Lesion morphology was classified according to the
American Heart Association/American College of Cardiol-
ogy (AHA/ACC) Classification Task Force with the ex-
ception that type B lesions were further stratified into B1
and B2 lesions according to Ellis et al. (14). It was the
responsibility of the operator to record device strategy and
utilization, intraprocedural adverse events and procedural
outcome on detailed forms. A lesion treatment was consid-
ered to be successful when there was a $20% gain in luminal
diameter and less than 50% residual diameter stenosis in the
absence of severe complications including death, Q-wave
myocardial infarction or emergency bypass surgery.
Vessel segments were classified according to the AHA/
ACC task force guidelines (15). Segments 1, 12 and 18 were
considered to be proximal in location. Segments 2 and 13
were by definition at midlocations and segments 3–10,
14–17 and 19–28 were considered distal in location. All
baseline angiograms were analyzed by a single technician
who was blinded for clinical data. The percent degree of
stenosis, reference and minimal luminal diameter were
determined after intracoronary administration of 100 mg of
nitroglycerin using a computer-assisted, automated edge
detection algorithm (Computer Measurements System,
MEDIS, Nuenen, The Netherlands) (16). Absolute refer-
ence diameter and minimal luminal diameter in millimeters
were determined using the guiding catheter filled with
contrast agent for calibration. Reference diameter was de-
termined automatically at the site of the obstruction using
an iterative linear regression technique. This automated
approach represented a reconstruction of the estimated size
of the vessel before the occurrence of a focal obstruction.
Statistical analysis. Continuous variables are expressed as
mean 6 SD and categorical variables as percent. Student t
test and chi-square analysis were carried out for comparison
of continuous and categorical variables, respectively. P
values #0.05 were considered significant. All analyses were
performed using SAS software version 6.10 (SAS Institute,
Cary, North Carolina). Reference diameters (#2.5 mm or
.2.5 mm) were entered as categorical variables. Demo-
graphic, clinical, procedural, angiographic and periproce-
dural variables were tested to determine significant univar-
iate correlates of combined major adverse events. Univariate
correlates with p values #0.05 were considered significant.
A multiple stepwise logistic regression analysis of all signif-
icant univariate factors was performed to determine inde-
pendent correlates of combined major events. Patients with
Abbreviations and Acronyms
AHA/ACC 5 American Heart Association/American
College of Cardiology
CK 5 creatine kinase
MACE 5 major adverse cardiac event (death,
Q-wave myocardial infarction and
emergency coronary artery bypass graft)
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small and large reference diameters were further stratified
into those with lesions treated at proximal, mid-, or distal
coronary segments, to compare the rate of major events
between the two groups with respect to treatment location.
To analyze whether stent utilization affected the relation-
ship between small reference artery diameter and major
adverse events, a subgroup analysis was performed on
patients receiving coronary stent placement.
RESULTS
Patient population. The study population included 2,306
patients with a mean age of 63 6 12 years. There were
1,548 men and 758 women. Overall, these patients reflect
most recent angioplasty registries with regard to patient
comorbidities, lesion-specific characteristics and devices
used for revascularization procedures (8,17–19).
Table 1 displays baseline demographic and clinical char-
acteristics and major in-hospital outcomes for patients with
reference diameters #2.5 mm (n 5 813 patients) and
.2.5 mm (n 5 1,493 patients). As compared with the large
vessel group, patients with lesions in small vessels were
older, more often female and more often affected by
diabetes, multivessel coronary disease, vascular disease, heart
failure and unstable angina (p # 0.01, each). Furthermore,
patients in the small vessel group presented less frequently
with evolving myocardial infarction, whereas history of
Table 1. Patient Characteristics (n 5 2,306 Patients)
RD <2.5 mm RD >2.5 mm p Value
Demographics
Patients 813 1,493
Age (yr) (mean 6 SD) 65 6 12 63 6 12 0.0001
Male 61% 70% 0.0001
Female 39% 30% 0.0001
Risk factors
Diabetes mellitus 27% 18% 0.0001
Hypertension 62% 59% NS
Elevated cholesterol 72% 74% NS
Smoking history 63% 68% 0.02
Family history CAD 62% 60% NS
Comorbidities
Prior myocardial infarction 35% 29% 0.001
Prior CABG 9% 6% 0.011
Prior coronary intervention 29% 24% 0.015
Multivessel disease 59% 49% 0.0001
COPD 7% 9% NS
Vascular disease (CVD or PVD) 15% 11% 0.002
Renal disease 11% 10% NS
LVEF (mean 6 SD) 56 6 13% 57 6 12% NS
Admission syndrome
Stable angina 8% 7% NS
Unstable angina (new, worse, rest) 54% 48% 0.006
Post-MI angina 13% 12% NS
Myocardial infarction 31% 38% 0.0007
Evolving MI (1–24 h to procedure) 6% 11% 0.0001
Cardiogenic shock 2% 2% NS
Congestive heart failure 9% 6% 0.007
In-hospital outcome
Death 3.0% 1.6% 0.0346
Q-wave MI 0.4% 0.3% NS
CABG (#24 h) 0.4% 0.3% NS
Combined (death, MI, CABG) 3.4% 2.0% 0.0395
Non–Q-wave MI 5.8% 5.0% NS
CABG (.24 h) 1.4% 1.3% NS
CABG 5 coronary artery bypass graft surgery; CAD 5 coronary artery disease; COPD 5 chronic obstructive pulmonary disease;
CVD 5 cerebrovascular disease; LVEF 5 left ventricular ejection fraction; MI 5 myocardial infarction; PVD 5 peripheral
vascular disease; RD 5 reference diameter.
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myocardial infarction, bypass grafting and prior coronary
intervention was observed more often (p , 0.01, each) in
this group.
Lesion characteristics and device utilization. Unfavor-
able AHA/ACC lesion type C morphology was found more
often in small vessels (p 5 0.003), as shown in Table 2.
Furthermore, successful percutaneous intervention, a gain of
$20% in diameter stenosis and a residual stenosis of less
than 50% without occurrence of a major adverse event
during the procedure was achieved in 92% of lesions in small
vessels and 95% of lesions in large vessels attempted for
coronary intervention (p 5 0.0006). Additionally, there
were also differences in device utilization between both
groups. Specifically, large vessels were more than twice as
likely to be treated with directional atherectomy or coronary
stenting (p # 0.0001, each), whereas those with small
vessels were more likely to be treated with conventional
balloon percutaneous transluminal coronary angioplasty or
rotational atherectomy (p # 0.0001, each). Furthermore,
lesions in vessels with small reference diameters were
preferentially found in distal coronary segments, whereas
reference diameters .2.5 mm were characteristic for prox-
imal vessel segments (p # 0.0001, each). During the course
of this study two important pharmacologic interventions
were introduced. First, the routine use of periprocedural
ticlopidine for patients receiving coronary stents was intro-
duced in May of 1995. Second, in this study cohort a total
of 65 patients received the glycoprotein receptor antagonist
ReoPro after April of 1996. There were no significant
differences in the utilization of this drug between both
groups of patients (2.2% vs. 3.2% for patients with reference
diameters #2.5 mm and .2.5 mm, respectively; p 5 0.19).
Major adverse events. Patients with lesions treated in
small vessels experienced an increased rate of in-hospital
Table 2. Lesion Characteristics (n 5 2,840 Lesions)
RD <2.5 mm RD >2.5 mm p Value
Lesions 1,012 1,828
Lesion success rate 92% 95% 0.0006
Reference diameter (mm) (mean 6 SD) 2.2 6 0.3 3.2 6 0.5 0.00001
Degree of stenosis
Preintervention 75 6 15% 76 6 15% NS
Postintervention 28 6 15% 25 6 15% 0.0001
Minimal luminal diameter (mm)
Preintervention (mean 6 SD) 0.6 6 0.6 0.9 6 0.6 0.0001
Postintervention (mean 6 SD) 1.7 6 0.5 2.4 6 0.6 0.0001
AHA/ACC lesion type
Type A 12% 11% NS
Type B1 34% 34% NS
Type B2 42% 47% 0.0204
Type C 10% 7% 0.0029
Device type
Conventional balloon PTCA 73% 50% 0.0001
Stent (primary and/or provisional) 18% 43% 0.0001
Directional atherectomy 4% 14% 0.0001
Rotational atherectomy 16% 8% 0.0001
Lesion location
Left main 0.3% 1% 0.0416
Proximal 28% 38% 0.0001
Mid 36% 37% NS
Distal/branches 35% 24% 0.0001
Vessel treated
Left main 0.3% 1% 0.0416
Right coronary 23% 44% 0.0001
Left anterior descending 53% 32% 0.0001
Circumflex 24% 23% NS
AHA/ACC 5 American Heart Association/American College of Cardiology; PTCA 5 percutaneous transluminal coronary
angioplasty; RD 5 reference diameter.
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combined major events (death, Q-wave myocardial infarc-
tion and emergency coronary artery bypass graft) as com-
pared with those with lesions treated in large vessels (3.4%
vs. 2.0%, respectively; p , 0.04). Significant univariate and
independent predictors of combined major adverse events
are shown in Tables 3 and 4. Note that small reference
artery diameter remained independently associated with an
increased rate of major adverse events even when the
stepwise regression model accounted for other unfavorable
clinical and morphologic factors. Furthermore, the associa-
tion between small reference artery diameter and the rate of
major adverse events was not altered (odds ratio 2.0,
confidence interval 1.2 to 3.3; p 5 0.006) when the
regression model was repeated in the entire 3,054 patients,
which included the 748 patients who received treatment in
vessels with both reference diameters.
Subgroup analyses revealed that the rate of combined
major adverse events differed substantially when interven-
tions at proximal or mid-, and distal coronary segments
were compared between the small and large vessel groups
(Fig. 1). Patients with small luminal reference diameters
who had lesions treated in a proximal or midcoronary
segment experienced a significantly higher rate of combined
major events than those with large reference diameters at
these locations (4.3% vs. 2.0%, respectively; p 5 0.007). In
particular, small luminal reference diameters of the proximal
left anterior descending coronary artery were associated with
nearly a sevenfold higher rate of major adverse events when
compared with respective reference diameters .2.5 mm at
the same location (7.6% vs. 1.1%; p 5 0.0007). In contrast,
lesions treated in distal coronary segments displayed low
event rates irrespective of vessel size (Fig. 1).
Non–Q-wave infarctions were observed more frequently
in the small vessel group (5.8%) as compared with the large
vessel group (5.0%), albeit the difference was not statistically
significant. Consequently, the frequency of the combined
Table 3. Univariate Analysis of Combined Major Events
Major Event
(With Feature)
Major Event
(Without Feature) p Value
Demographics
0.0178
Age procedure performed (yr)
(mean 6 SD)
71 6 12 63 6 11 0.0001
Female gender 3.8% 1.9% 0.0064
Risk factors
Diabetes mellitus 4.7% 1.9% 0.0009
Hypertension 3.2% 1.2% 0.0028
Comorbidities
Prior coronary intervention 1.2% 2.9% 0.0202
Multivessel disease 4.1% 1.7% 0.0012
COPD 5.5% 2.2% 0.0123
Vascular disease (CVD or PVD) 4.3% 2.1% 0.0351
Renal disease 10.8% 1.6% 0.0001
LVEF (mean 6 SD) 49 6 17% 57 6 12% 0.0004
Admission syndrome
Unstable angina (new, worse, rest) 0.9% 4.2% 0.0001
Myocardial infarction 4.8% 1.2% 0.0001
Evolving MI (1–24 h to procedure) 11.4% 1.6% 0.0001
Cardiogenic shock 43.8% 1.6% 0.0001
Congestive heart failure 11.8% 1.8% 0.0001
AHA/ACC lesion type
Type B1 1.6% 3.0% 0.0374
Type C 7.8% 1.9% 0.0001
Total lesions treated 1.4 6 0.7 1.2 6 0.5 0.0073
Reference diameter #2.5 mm 3.4% 2.0% 0.0395
Device type
Conventional balloon PTCA 3.4% 1.1% 0.0003
Stent 1.3% 3.2% 0.0053
Abbreviations as in Tables 1 and 2.
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secondary end point of major adverse events (death or
Q-wave myocardial infarction or emergency coronary artery
bypass graft) and non–Q-wave infarctions was higher in the
small vessel group (9.2% vs. 7.0%; p , 0.05).
Major recent trends. Between 1994 and 1996, the rate of
combined major adverse events declined significantly from
3.5% to 1.3% (p 5 0.01). Table 5 displays annual rates of
combined major adverse events and lesion treatment success
rates by reference vessel group. Whereas the complication
rate decreased significantly over time in the large vessel
group, the improvement in the group with reference diam-
eters #2.5 mm was only modest and statistically not
significant. Likewise, the increase in lesion treatment suc-
cess over time was significant only in the large vessel group.
In parallel, the rate of stent utilization increased signifi-
cantly from 8% to 63% (p # 0.0001) during this three-year
observational period. Since stent treatment was preferen-
tially used in the large vessel group (Table 2), the lower rate
of stent utilization in the small vessel group may have
contributed to the higher periprocedural risk of these
patients. To test this hypothesis we studied a subgroup of
835 patients receiving stents (167 patients with reference
vessel diameters of #2.5 mm and 668 patients with refer-
ence vessel diameter .2.5 mm) to determine whether small
reference artery diameter is also a risk predictor in patients
receiving stents. As shown in Table 3, major adverse events
were infrequent in patients receiving stents (1.3% vs. 3.2%;
p 5 0.005 for patients receiving and not receiving stents,
respectively). Interestingly, small reference artery diameter
was not found to be a correlate of in-hospital MACEs, in
this subgroup of 835 patients receiving stents.
DISCUSSION
The central finding of the present study is that percutaneous
revascularization procedures of coronary vessels with lumi-
nal reference diameters of #2.5 mm are associated with
lower rates of procedural success and higher rates of subse-
quent in-hospital major events. A novel discovery of this
study is that coronary interventions involving proximal
vessels of small caliber appear to be a major adverse
prognostic factor. Moreover, patients with such small cor-
onary vessels are characterized by other unfavorable comor-
bid or lesion-specific conditions. Altogether, it appears that
a small luminal reference diameter at the lesion site consti-
tutes a prognostic factor that may provide refined informa-
tion to predict the outcome of an attempted interventional
coronary revascularization procedure.
Small vessels and associated risk factors for coronary
interventions. Previous studies have identified a number
of patient- and coronary artery–related factors that pre-
dict elevated risks of attempted percutaneous coronary
revascularization procedures (7,17–21). It is of interest
that some of these conditions, such as female gender and
diabetes mellitus, are associated with smaller epicardial
arterial diameters (22,23). In agreement with those stud-
ies, patients with small luminal reference diameters of the
Figure 1. The figure displays rates of major adverse events (death,
Q-wave myocardial infarction, emergency bypass surgery) associ-
ated with interventional revascularization procedures. Vessels with
small (#2.5 mm) versus large (.2.5 mm) luminal reference
diameter were compared after transcatheter interventions at prox-
imal left anterior descending, proximal and mid-, and distal vessel
locations. A small luminal reference diameter was associated with
significantly higher complication rates, specifically when lesions at
proximal left anterior descending or proximal and midvessel
locations were treated interventionally. LAD 5 left anterior
descending artery.
Table 4. Logistic Regression Analysis of Combined Major Events
Covariate
Odds
Ratio
95% CI
p
ValueLower Upper
Small vs. large vessel group 2.123 1.098 4.098 0.025
AHA/ACC lesion type C 2.651 1.268 5.542 0.010
Total number of lesions treated 1.629 1.075 2.468 0.021
Age (per year) 1.043 1.014 1.072 0.004
Diabetes mellitus 2.206 1.132 4.298 0.020
Renal disease 3.941 2.034 7.637 0.0001
Unstable angina (new, worse, rest) 0.363 0.162 0.817 0.014
Cardiogenic shock 11.660 4.619 29.437 0.0001
Evolving myocardial infarction 2.797 1.203 6.500 0.017
AHA/ACC 5 American Heart Association/American College of Cardiology; CI 5 confidence interval.
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present registry were found to be older, more often
female or characterized by diabetes mellitus, peripheral
vascular disease, carotid disease, multivessel coronary
disease or history of myocardial infarction or bypass
grafting. In addition, small reference diameters were
often associated with unfavorable AHA/ACC type C
lesion morphology, which is another powerful factor to
predict both a decreased success rate and an elevated
periprocedural risk (14,20). To account for enhanced
patient comorbidities and unfavorable lesion morpholo-
gies in the small vessel group, we adjusted for these
factors using a stepwise logistic regression model. The
analysis revealed that small luminal reference diameter
appeared to predict lower rates of procedural success and
higher rates of subsequent major adverse events indepen-
dently from these group-specific cofactors. In fact, some
clinical predictors such as female gender were not found
to be associated with major adverse events after correc-
tion for vessel size in this analysis. Thus, it may be
hypothesized that some of the risks associated with these
clinical predictors may be secondary to the fact that these
patients often present with small coronary arteries and
therefore, unfavorable coronary artery morphology. It has
to be noted, however, that these conclusions are based on
a retrospective analysis of a prospectively established
angioplasty registry. Furthermore, although patient ana-
tomic and procedural variables have been included in the
model, multivariate analysis does not account for all
differences between groups. Therefore, further confirma-
tion from prospective trials is required to firmly establish
this information.
Proximal vessels of small caliber, a major adverse prog-
nostic factor. The present study demonstrated that the risk
for major events is particularly high when a proximal or
midcoronary segment has a luminal diameter #2.5 mm. In
fact, the rate of periprocedural major adverse events was
sevenfold higher in patients with small proximal left anterior
descending arteries than in those with large proximal left
anterior descending arteries. This elevated risk is most likely
due to the absence of adequate bailout techniques available
to treat suboptimal angioplasty results in small vessels, even
though vessels at proximal locations perfuse large areas of
myocardium. In contrast, a small reference diameter at a
distal location was without predictive value. Furthermore, it
may be speculated that a small reference diameter at a
proximal or midsegment location is a marker for the
presence of more severe coronary artery disease. For exam-
ple, patients with diabetes mellitus have been shown to have
small reference diameters as a consequence of higher plaque
burden and more diffuse disease (24,25). Thus, the associ-
ation of unfavorable comorbid factors with small reference
diameters may reflect diffuse coronary artery disease that is
more likely to result in major complications such as death,
Q-wave or non–Q-wave myocardial infarctions, emergency
coronary artery bypass grafting or, as previously demon-
strated, subsequent restenosis (26,27). This opinion receives
further support from experience with surgical revasculariza-
tion that indicates a substantial increase in perioperative
mortality if a left anterior descending artery in patients
undergoing coronary bypass surgery is smaller than 2.5 mm
in luminal diameter (28,29).
Table 5. Major Recent Trends
1994 1995 1996
p Value,
Overall
Trend
Major event rate
Small vessel group 4.0% 4.2% 2.0% NS
Large vessel group 3.0% 2.2% 0.9% 0.047
Lesion success rate
Small vessel group 90.8% 91.7% 94.3% NS
Large vessel group 92.2% 95.6% 97.7% # 0.0001
Lesion device utilization
Conventional balloon PTCA
Small vessel group 83.9% 74.7% 61.3% # 0.0001
Large vessel group 64.4% 60.4% 35.7% # 0.0001
Stent
Small vessel group 5.2% 22.6% 40.3% # 0.0001
Large vessel group 9.7% 46.1% 73.8% # 0.0001
Directional atherectomy
Small vessel group 6.3% 2.8% 3.2% NS
Large vessel group 31.8% 10.5% 5.2% # 0.0001
Rotational atherectomy
Small vessel group 17.0% 17.1% 17.7% NS
Large vessel group 11.7% 8.3% 6.5% 0.0167
PTCA 5 percutaneous transluminal coronary angioplasty.
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Small vessel interventions in the new device era. The
present association between small luminal reference diam-
eter and adverse in-hospital events appears to contrast with
previous registries of patients undergoing interventional
coronary revascularization procedures (2,3). However, pre-
vious studies as well as the experience that led to the
AHA/ACC stratification of coronary morphologies were
based on the predominant use of conventional balloon
angioplasty. More recently, profound changes in interven-
tional technology have taken place and were related to an
increase in procedural success rates and a decrease in the rate
of major adverse events (5,6,8). The present registry con-
firms this trend (7). However, some new devices such as
stents or directional coronary atherectomy catheters have
specific limitations in the treatment of small vessels (9–12).
Indeed, in this registry only a minority of patients with
vessel diameter of #2.5 mm have been treated with these
devices. Hence, it may be postulated that the benefit of the
new device era is largely confined to patients with coronary
arteries .2.5 mm. In accordance with this hypothesis are
two trends observed in this registry. Namely, the increase in
procedural success rate and decrease in major adverse event
rate were significant only for lesions located in large coro-
nary arteries.
With the continued refinement in angioplasty techniques
and new device evolution, lesion morphologic determinants
of angioplasty outcome may have changed significantly.
One may speculate, for example, that the progress in the
interventional treatment of complex lesions is largely con-
fined to vessels with the appropriate size to harbor a stent.
Although this hypothesis requires confirmation by con-
trolled studies, two potential clinical implications may
deserve consideration. First, the observation that interven-
tional treatment of small vessels carries higher risks and is
associated with a lower chance of success clearly defines a
coronary morphology that may benefit from further im-
provements in device technology or interventional strate-
gies. Second, the current practice to largely limit the use of
stents to vessels .2.5 mm requires reevaluation. Our results
of no significant differences in the rate of major adverse
events in patients receiving stent placement regardless of the
reference vessel diameter are encouraging. Thus, it appears
from the present data that there is a need for the develop-
ment of stents appropriately designed to treat small diam-
eter vessels, as the utilization of stents was limited to 18% of
patients with small vessels as compared with 43% of those
with large vessels. However, a prospective, randomized trial
comparing balloon angioplasty with stent placement using
specifically designed stents for smaller coronary arteries
(#2.5 mm) is necessary. Since there may be an increased
risk for stent thrombosis in small vessels (30,31), the impact
of these devices needs to be investigated prospectively not
only with respect to restenosis rates (11,12), but also with
respect to the rates of periprocedural success and major
adverse events.
Vessel size is a critical anatomic factor inversely related to
restenosis rate. In the M-HEART study of patients under-
going conventional balloon angioplasty, Hirshfeld et al.
reported a significantly higher restenosis rate of 44% in
vessels ,2.9 mm compared with 34% in vessels .2.9 mm
(32). Therefore, interventions designed to reduce restenosis
such as coronary stents would have a greater impact if
applicable to smaller vessels. In fact in a substudy analysis of
the STRESS trial (33), Savage et al. reported a restenosis
rate of 33% in 139 patients with a mean reference vessel
diameter of 2.69 6 0.21 mm treated with stenting and a
restenosis rate of 54% in 121 patients with a mean reference
vessel diameter of 2.64 6 0.24 mm treated with conven-
tional balloon angioplasty (p 5 0.001). The corresponding
target artery revascularization was 19% and 31% for the
stent and the angioplasty groups, respectively (p 5 0.019).
These findings suggest that elective stent placement may be
highly effective for smaller vessels. Since in the present study
36% of percutaneous interventional procedures were per-
formed in vessels #2.5 mm in diameter, demonstration of
the efficacy of stents in this subgroup would significantly
enlarge the patient population who would benefit from this
technique.
Conclusions. The present study suggests that the luminal
reference diameter of the coronary artery that carries the
culprit lesion, particularly when it is located in the proximal
segments of the coronary arteries, is a powerful predictor of
periprocedural risks and success rates.
Study limitations. We recognize certain limitations of this
study. First, the present study addressed only in-hospital
events (success, in-hospital MACEs and non–Q-wave myo-
cardial infarction). Although previous studies have demon-
strated that small vessels treated with conventional balloon
angioplasty have an inferior long-term follow-up outcome
(32,33), it is possible that long-term follow-up may also
differ in these patients in the current device era. Second, our
conclusions are based on a retrospective analysis of a
prospectively established angioplasty registry and further
confirmation from prospective trials is required to firmly
establish this information. Finally, although stent implan-
tation seems to be the more likely reason for the decrease of
the in-hospital major complication rate, other factors such
as the periprocedural administration of ticlopidine or Reo-
Pro may have also contributed to the decrease of the
in-hospital MACEs. A prospective randomized trial of
balloon angioplasty versus coronary stenting in a small vessel
group is necessary to address these important but yet
unanswered questions.
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